Key facts
- This page summarizes Mark Christopher Capone's Form 4 filing for DermTech, Inc..
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 20 Jul 2022, 20:12.
Mark Christopher Capone - 18 Jul 2022 Form 4 Insider Report for DermTech, Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 18 Jul 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 20 Jul 2022, 20:12:48 UTC
- Next SEC filing
- 05 Jun 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jason S. Miller, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Mark Christopher Capone filed Form 4 for DermTech, Inc. on 20 Jul 2022.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
DMTK
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +26,480
- Change %
- Price
- $0.000000
- Shares after
- 26,480
- Date
- 18 Jul 2022
- Ownership
- Direct
- Footnotes
- F1
DMTK
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +19,860
- Change %
- +75%
- Price
- $0.000000
- Shares after
- 46,340
- Date
- 18 Jul 2022
- Ownership
- Direct
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The securities awarded are in the form of restricted stock units issued pursuant to the issuer's 2020 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of issuer common stock. The restricted stock units shall vest in three equal annual installments over the three-year period following the grant date, subject to the reporting person's continued service.
Footnote F2
The securities awarded are in the form of restricted stock units issued pursuant to the issuer's 2020 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of issuer common stock. The restricted stock units shall vest in one installment on May 26, 2023.